Healthcare [ 7/13 ] | Biotechnology [ 82/163 ]
NASDAQ | Common Stock
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders.
Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD.
The company has a research collaboration agreement with Allergan plc.
Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 15, 23 | 0.00 Increased by +100.00% | -0.05 Increased by +100.00% |
| Aug 4, 23 | 0.00 Increased by +100.00% | -0.05 Increased by +100.00% |
| May 18, 23 | -0.18 Increased by +37.93% | -0.14 Decreased by -28.57% |
| Mar 30, 23 | -0.18 Increased by +37.93% | -0.19 Increased by +5.26% |
| Nov 8, 22 | -0.23 Increased by +25.81% | -0.24 Increased by +4.17% |
| Aug 4, 22 | -0.26 Increased by +10.34% | -0.28 Increased by +7.14% |
| May 12, 22 | -0.29 Decreased by -31.82% | -0.30 Increased by +3.33% |
| Mar 23, 22 | -0.29 Decreased by -45.00% | -0.35 Increased by +17.14% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 23 | 0.00 Decreased by N/A% | -21.81 M Decreased by -7.57% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | 25.97 M Increased by +232.43% | Increased by +N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by -100.00% | -15.10 M Increased by +28.90% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by -100.00% | -18.23 M Increased by +8.02% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by -100.00% | -20.27 M Decreased by -42.52% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -19.61 M Decreased by -70.70% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 21 | 4.93 K Decreased by -98.08% | -21.23 M Decreased by -87.26% | Decreased by -430.82 K% Decreased by -9.67 K% |
| Jun 30, 21 | 5.07 M Increased by +934.69% | -19.82 M Decreased by -58.34% | Decreased by -390.91% Increased by +84.70% |